NovaBay Pharmaceuticals, Inc., an advanced clinical-stage biopharmaceutical company developing topical antimicrobial products, today released a video of its Analyst and Investor Event which was held on September 17th in New York City.
At the event, Dr. Ron Najafi, Chairman and Chief Executive Officer of NovaBay, provided an overview of the company’s goals and milestones reached. NovaBay senior management team along with the clinicians involved in the study and key opinion leaders presented the data from NovaBay’s phase 2 clinical study of auriclosene to reduce urinary catheter blockage and encrustation (UCBE) of indwelling urinary catheters.
UCBE Analyst Day Video
NovaBay Highlights Data from Phase 2 UCBE Study. Video can be viewed here. Highlighted in the video are:
• Ron Najafi, Ph.D., Chairman and CEO, NovaBay
• Keith R. Bley, Ph.D., Senior Vice President of Product Development, NovaBay;
• Todd Linsenmeyer, M.D., Director of Urology at the Kessler Institute for Rehabilitative Medicine in West Orange, NJ and the principal investigator in NovaBay’s phase 2 UCBE study;
• V. Spencer Long, M.D., Urologist at J.C. Blair Memorial Hospital in Huntingdon, PA; and;
• Mary Wilde, Ph.D., R.N., Associate Professor of Nursing at the University of Rochester Medical Center.
Press release, patient and physician video, presentation, and video from the UCBE analyst and investor event are available on NovaBay’s website.
Due to spinal cord injuries, multiple sclerosis, strokes, or neurogenic bladder conditions, an estimated 100,000 patients in the U.S. have indwelling catheters and episodically suffer from blockage and encrustation. In these patients, catheters repeatedly become colonized with bacteria and bacterial biofilm, which may produce localized crystal deposits that may build up and block the catheter. Urinary catheter blockages pose health risks to these patients and are a contributor to medical emergencies, increased health care costs and decreased quality of life.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics
NovaBay Pharmaceuticals is an advanced clinical-stage biopharmaceutical company focused on addressing the large unmet therapeutic needs of the global, topical anti-infective market with its Aganocide compounds, led by auriclosene. Auriclosene is a new chemical entity invented by NovaBay which has a broad spectrum of activity against bacteria, viruses and fungi. Aganocide compounds are based on the human body’s natural immune system and the molecules involved in combating infections. Bacterial resistance to Aganocides is highly unlikely, as demonstrated in in vitro studies. Once pathogens penetrate the body’s primary defense, the next line of defense is provided by the white blood cells. NovaBay has focused on understanding these molecules generated by the white blood cells and finding ways, by chemical modification, to allow them to be developed as therapeutic products with the potential to treat a wide range of local, non-systemic infections. As Aganocides® begin to supplement and thereby reduce the usage of classic topical antibiotics, they will help slow the rise of antibiotic resistance.
This release contains forward-looking statements, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the potential for auriclosene to dramatically reduce problems of unpredictable early catheter blockage, to reduce healthcare costs and to make a substantial difference in the lives of patients with long-term indwelling catheters, and NovaBay’s plans to continue discussions with the FDA. The words “can,” “may,” “would,” and “plans” and other words (and all variations of these words that imply future events), identify these statements as forward looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in development, clinical trial, regulatory approval, production and marketing of the company’s product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. These risks and others are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
NovaBay Pharmaceuticals Contacts
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson
Director, Investor Relations and Corporate Communications
NovaBay Pharmaceuticals, Inc.
Contact Ana Kapor